Cargando…

克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌

BACKGROUND AND OBJECTIVE: Lung cancer with brain metastasis had poor prognosis.Crizotinib had been confirmed to be used in ROS1 (C-ros oncogene 1 receptor tyrosine kinase) rearranged lung adenocarcinoma, but its efficacy in lung cancer with brain metastasis was poor due to the blood brain barrier.In...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972988/
https://www.ncbi.nlm.nih.gov/pubmed/27561802
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.07
_version_ 1783326515679723520
collection PubMed
description BACKGROUND AND OBJECTIVE: Lung cancer with brain metastasis had poor prognosis.Crizotinib had been confirmed to be used in ROS1 (C-ros oncogene 1 receptor tyrosine kinase) rearranged lung adenocarcinoma, but its efficacy in lung cancer with brain metastasis was poor due to the blood brain barrier.In the present study, we reported one case of ROS1 fusion lung adenocarcinoma with symptomatic brain matastasis, who was treated with brain metastases resection, crizotinib, and whole brain radiotherapy plus boost to residual brain metastasis.The safety and efficacy was summarized. METHODS: At first, surgical resection was used to relive mass effect and to biopsy.Then crizotinib (250 mg, bid) was chosen for the existence of ROS1 fusion gene.Whole brain radiotherapy plus boost to residual brain metastasis were used after surgery.Objective response was evaluated by Response Evaluation Criteriation in Solid Tumours (RECIST) v1.1 and brain metastasis were evaluated by computer tomography (CT)/magnetic resonance imaging (MRI) image.Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTC AE) v4.0. RESULTS: After taking crizotinib for 3 months, the lung lesions were close to complete response (CR), the brain metastasis were partial response (PR), the abdomen metastasis were CR and the symptom of blurred vision relieved. CONCLUSION: Crizotinib combined with palliative operation and radiation therapy (WBRT plus boost to residual brain metastasis) in the treatment of ROS1 fusion gene positive lung adenocarcinoma with symptomatic brain metastases, can effectively control intracranial lesions with good tolerance.
format Online
Article
Text
id pubmed-5972988
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59729882018-07-06 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌 Zhongguo Fei Ai Za Zhi 肺癌脑转移专题 BACKGROUND AND OBJECTIVE: Lung cancer with brain metastasis had poor prognosis.Crizotinib had been confirmed to be used in ROS1 (C-ros oncogene 1 receptor tyrosine kinase) rearranged lung adenocarcinoma, but its efficacy in lung cancer with brain metastasis was poor due to the blood brain barrier.In the present study, we reported one case of ROS1 fusion lung adenocarcinoma with symptomatic brain matastasis, who was treated with brain metastases resection, crizotinib, and whole brain radiotherapy plus boost to residual brain metastasis.The safety and efficacy was summarized. METHODS: At first, surgical resection was used to relive mass effect and to biopsy.Then crizotinib (250 mg, bid) was chosen for the existence of ROS1 fusion gene.Whole brain radiotherapy plus boost to residual brain metastasis were used after surgery.Objective response was evaluated by Response Evaluation Criteriation in Solid Tumours (RECIST) v1.1 and brain metastasis were evaluated by computer tomography (CT)/magnetic resonance imaging (MRI) image.Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTC AE) v4.0. RESULTS: After taking crizotinib for 3 months, the lung lesions were close to complete response (CR), the brain metastasis were partial response (PR), the abdomen metastasis were CR and the symptom of blurred vision relieved. CONCLUSION: Crizotinib combined with palliative operation and radiation therapy (WBRT plus boost to residual brain metastasis) in the treatment of ROS1 fusion gene positive lung adenocarcinoma with symptomatic brain metastases, can effectively control intracranial lesions with good tolerance. 中国肺癌杂志编辑部 2016-08-20 /pmc/articles/PMC5972988/ /pubmed/27561802 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.07 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 肺癌脑转移专题
克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title_full 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title_fullStr 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title_full_unstemmed 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title_short 克唑替尼联合脑转移灶切除、全脑放疗治疗ROS1阳性伴有症状脑转移的肺腺癌
title_sort 克唑替尼联合脑转移灶切除、全脑放疗治疗ros1阳性伴有症状脑转移的肺腺癌
topic 肺癌脑转移专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972988/
https://www.ncbi.nlm.nih.gov/pubmed/27561802
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.07
work_keys_str_mv AT kèzuòtìníliánhénǎozhuǎnyízàoqièchúquánnǎofàngliáozhìliáoros1yángxìngbànyǒuzhèngzhuàngnǎozhuǎnyídefèixiànái
AT kèzuòtìníliánhénǎozhuǎnyízàoqièchúquánnǎofàngliáozhìliáoros1yángxìngbànyǒuzhèngzhuàngnǎozhuǎnyídefèixiànái
AT kèzuòtìníliánhénǎozhuǎnyízàoqièchúquánnǎofàngliáozhìliáoros1yángxìngbànyǒuzhèngzhuàngnǎozhuǎnyídefèixiànái